Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab
出版年份 2015 全文链接
标题
Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab
作者
关键词
-
出版物
ANNALS OF PHARMACOTHERAPY
Volume 49, Issue 12, Pages 1327-1335
出版商
SAGE Publications
发表日期
2015-10-01
DOI
10.1177/1060028015608487
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia
- (2015) Eliano Pio Navarese et al. ANNALS OF INTERNAL MEDICINE
- Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
- (2015) Xin-Lin Zhang et al. BMC Medicine
- Biosimilar Competition In The United States: Statutory Incentives, Payers, And Pharmacy Benefit Managers
- (2015) Benjamin P. Falit et al. HEALTH AFFAIRS
- Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta-Analysis of 20 Randomized Controlled Trials
- (2015) C. Li et al. Journal of the American Heart Association
- Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data
- (2014) Arrigo FG Cicero et al. Expert Opinion On Drug Safety
- The Severe Hypercholesterolemia Phenotype
- (2014) Allan D. Sniderman et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Lipid lowering with PCSK9 inhibitors
- (2014) Razvan T. Dadu et al. Nature Reviews Cardiology
- Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges
- (2014) Giuseppe Danilo Norata et al. VASCULAR PHARMACOLOGY
- Lipoprotein apheresis: State of the art and novelties
- (2013) C. Stefanutti et al. ATHEROSCLEROSIS SUPPLEMENTS
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
- (2013) Neil J. Stone et al. CIRCULATION
- PCSK9 inhibitors
- (2013) Michel Farnier CURRENT OPINION IN LIPIDOLOGY
- Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation
- (2013) Gerald F. Watts et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Treatment of adults with Familial Hypercholesterolemia and evidence for treatment: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
- (2011) Jennifer G. Robinson et al. Journal of Clinical Lipidology
- Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- PCSK9R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease
- (2010) Marianne Benn et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study
- (2008) A. Neil et al. EUROPEAN HEART JOURNAL
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
- (2008) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started